AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1.-45. **(Canceled)**

46. **(New)** A protein complex comprising:

(a) at least one first protein selected from the group consisting of:

(i) "ANDROGEN RECEPTOR" (SEQ ID No:1), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "ANDROGEN RECEPTOR" encoded by a nucleic acid that hybridizes to the "ANDROGEN RECEPTOR" nucleic acid or its complement under low stringency conditions;

(ii) "Actin" (SEQ ID No:2), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "Actin" encoded by a nucleic acid that hybridizes to the "Actin" nucleic acid or its complement under low stringency conditions;

(iii) "BAF53" (SEQ ID No:3), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "BAF53" encoded by a nucleic acid that hybridizes to the "BAF53" nucleic acid or its complement under low stringency conditions;

(iv) "ECP-51" (SEQ ID No:6), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "ECP-51" encoded by a nucleic acid that hybridizes to the "ECP-51" nucleic acid or its complement under low stringency conditions;

(v) "HDAC1" (SEQ ID No:10), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "HDAC1" encoded by a nucleic acid that hybridizes to the

"HDAC1" nucleic acid or its complement under low stringency conditions;

(vi) "PAF400/TRRAP" (SEQ ID No:12), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "PAF400/TRRAP" encoded by a nucleic acid that hybridizes to the "PAF400/TRRAP" nucleic acid or its complement under low stringency conditions;

(vii) "RUVBL1/ECP-54 (Pontin)" (SEQ ID No:14), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "RUVBL1/ECP-54 (Pontin)" encoded by a nucleic acid that hybridizes to the "RUVBL1/ECP-54 (Pontin)" nucleic acid or its complement under low stringency conditions; and

(viii) "TIP60" (SEQ ID No:17), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "TIP60" encoded by a nucleic acid that hybridizes to the "TIP60" nucleic acid or its complement under low stringency conditions;

and

(b) at least one second protein, which second protein is selected from the group consisting of:

(i) "C20orf20" (SEQ ID No:4), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "C20orf20" encoded by a nucleic acid that hybridizes to the "C20orf20" nucleic acid or its complement under low stringency conditions;

(ii) "DMAP1" (SEQ ID No:5), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "DMAP1" encoded by a nucleic acid that hybridizes to the "DMAP1" nucleic acid or its complement under low stringency conditions;

(iii) "EP400: E1A binding protein p400" (SEQ ID No:7), a functionally active derivative thereof, a functionally active fragment thereof, a

homolog thereof, or a variant of "EP400: E1A binding protein p400" encoded by a nucleic acid that hybridizes to the "EP400: E1A binding protein p400" nucleic acid or its complement under low stringency conditions;

(iv) "EPC1" (SEQ ID No:8), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "EPC1" encoded by a nucleic acid that hybridizes to the "EPC1" nucleic acid or its complement under low stringency conditions;

(v) "GAS41 (glioma-amplified sequence-41)" (SEQ ID No:9), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "GAS41 (glioma-amplified sequence-41)" encoded by a nucleic acid that hybridizes to the "GAS41 (glioma-amplified sequence-41)" nucleic acid or its complement under low stringency conditions;

(vi) "KIAA1093 (Fragment)" (SEQ ID No:11), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "KIAA1093 (Fragment)" encoded by a nucleic acid that hybridizes to the "KIAA1093 (Fragment)" nucleic acid or its complement under low stringency conditions;

(vii) "RBM14" (SEQ ID No:13), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "RBM14" encoded by a nucleic acid that hybridizes to the "RBM14" nucleic acid or its complement under low stringency conditions;

(viii) "SWI/SNF COMPLEX 60 KDA SUBUNIT" (SEQ ID No:15), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "SWI/SNF COMPLEX 60 KDA SUBUNIT" encoded by a nucleic acid that hybridizes to the "SWI/SNF COMPLEX 60 KDA SUBUNIT" nucleic acid or its complement under low stringency conditions;

(ix) "THR coactivating protein" (SEQ ID No:16), a functionally active derivative thereof, a functionally active fragment thereof, a homolog

thereof, or a variant of "THR coactivating protein" encoded by a nucleic acid that hybridizes to the "THR coactivating protein" nucleic acid or its complement under low stringency conditions; and

(x) "YL-1" (SEQ ID No:18), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "YL-1" encoded by a nucleic acid that hybridizes to the "YL-1" nucleic acid or its complement under low stringency conditions,

wherein the low stringency conditions comprise (a) hybridization in a buffer comprising about 35% formamide, about 5X SSC, about 50 mM Tris-HCI (about pH 7.5), about 5 mM EDTA, about 0.02% PVP, about 0.02% Ficoll, about 0.2% BSA, about 100 μg/ml denatured salmon sperm DNA, and about 10% (wt/vol) dextran sulfate for about 18 to about 20 hours at about 40 Celsius, (b) washing in a buffer consisting of about 2X SSC, about 25 mM Tris-HCI (about pH 7.4), about 5 mM EDTA, and about 0.1 % SDS for about 1.5 hours at about 55 Celsius, and (c) washing in a buffer consisting of about 2X SSC, about 25 mM Tris-HCI (about pH 7.4), about 5 mM EDTA, and about 0.1% SDS for about 1.5 hours at about 60 Celsius.

47. **(New)** The protein complex of claim 46, comprising at least two of the second proteins.

48. **(New)** The protein complex of claim 46, wherein the second protein is selected from the group consisting of C20orf20 and KIAA1093.

49. **(New)** A method for screening for a molecule that binds either to the protein complex of Claim 46 or to any of its protein components, preferably to:

(a) "C20orf20" (SEQ ID No:4), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "C20orf20" encoded by a nucleic acid that hybridizes to the "C20orf20" nucleic acid or its complement under low stringency conditions, or to

(b) "KIAA1093 (Fragment)" (SEQ ID No:11), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "KIAA1093 (Fragment)" encoded by a nucleic acid that hybridizes to the

"KIAA1093 (Fragment)" nucleic acid or its complement under low stringency conditions,

wherein the low stringency conditions comprise (a) hybridization in a buffer comprising about 35% formamide, about 5X SSC, about 50 mM Tris-HCI (about pH 7.5), about 5 mM EDTA, about 0.02% PVP, about 0.02% Ficoll, about 0.2% BSA, about 100 µg/ml denatured salmon sperm DNA, and about 10% (wt/vol) dextran sulfate for about 18 to about 20 hours at about 40 Celsius, (b) washing in a buffer consisting of about 2X SSC, about 25 mM Tris-HCI (about pH 7.4), about 5 mM EDTA, and about 0.1 % SDS for about 1.5 hours at about 55 Celsius, and (c) washing in a buffer consisting of about 2X SSC, about 25 mM Tris-HCI (about pH 7.4), about 5 mM EDTA, and about 0.1% SDS for about 1.5 hours at about 60 Celsius;

the method comprising the steps of:

(a) exposing the complex or protein component, or a cell or organism containing the complex or protein component, to one or more candidate molecules; and

(b) determining whether the candidate molecule is bound to the complex or protein component.

50. **(New)** The method of claim 49, wherein the method is for screening for a molecule that modulates directly or indirectly the function, activity, composition, or formation of the complex or protein component.

51. **(New)** The method of claim 49, wherein the determining step comprises:

(a) isolating from the cell or organism the complex or protein component to produce the isolated complex or protein component;

(b) contacting the isolated complex in the presence or absence of a candidate molecule with a substrate of the complex or protein component; and

(c) determining whether the processing of the substrate is modified in the presence of the candidate molecule.

52. **(New)** The method of claim 49, wherein the method is a method of screening for a drug for treatment or prevention of a disease or disorder such as neurodegenerative diseases such as Alzheimer's disease.

53. **(New)** The method of claim 50, wherein the method is for screening of a molecule modulating the apoptotic activity of the complex or the influence of the protein on the apoptotic activity of the complex.

54. **(New)** The method of claim 50, further comprising mixing the identified molecule with a pharmaceutically acceptable carrier.

55. **(New)** A method for treating or preventing a disease or disorder characterized by an aberrant amount, activity, component composition, or activity of the protein complex of Claim 1 or of any of its protein components, preferably of:

(a) "C20orf20" (SEQ ID No:4), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "C20orf20" encoded by a nucleic acid that hybridizes to the "C20orf20" nucleic acid or its complement under low stringency conditions; or to

(b) "KIAA1093 (Fragment)" (SEQ ID No:11), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "KIAA1093 (Fragment)" encoded by a nucleic acid that hybridizes to the "KIAA1093 (Fragment)" nucleic acid or its complement under low stringency conditions,

wherein the low stringency conditions comprise (a) hybridization in a buffer comprising about 35% formamide, about 5X SSC, about 50 mM Tris-HCI (about pH 7.5), about 5 mM EDTA, about 0.02% PVP, about 0.02% Ficoll, about 0.2% BSA, about 100 µg/ml denatured salmon sperm DNA, and about 10% (wt/vol) dextran sulfate for about 18 to about 20 hours at about 40 Celsius, (b) washing in a buffer consisting of about 2X SSC, about 25 mM Tris-HCI (about pH 7.4), about 5 mM EDTA, and about 0.1 % SDS for about 1.5 hours at about 55 Celsius, and (c) washing in a buffer consisting of about 2X SSC, about 25 mM Tris-HCI (about pH 7.4), about 5 mM EDTA, and about 0.1% SDS for about 1.5 hours at about 60 Celsius;

the method comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of one or more molecules that modulate either directly or indirectly the function, activity, the apoptotic activity, composition, or formation of the complex, or of a protein component of the complex, or the influence of the protein component on the apoptotic activity of the complex.

56. **(New)** The method according to Claim 55, wherein the disease or disorder is Alzheimer's disease.